Zacks Investment Research·1 day ago
Implied Volatility Surging for Niagen Bioscience Stock OptionsInvestors need to pay close attention to NAGE stock based on the movements in the options market lately.
Niagen Bioscience Inc(NAGE)Earnings, Financials & Key Ratios
NAGE•NASDAQ
$3.45
17.3× P/E·Price updated Jul 7, 2026
AboutNiagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.Show more
- Revenue$129M+29.9%
- EBITDA$16M+71.0%
- Net Income$17M+103.3%
- EPS (Diluted)0.20+81.8%
- Gross Margin64.28%+3.9%
- EBITDA Margin12.17%+31.6%
- Operating Margin11.05%+42.4%
- Net Margin13.43%+56.4%
- ROE28.35%+23.6%
NAGE Price & Volume
Niagen Bioscience Inc (NAGE) stock price & volume — 10-year historical chart
Loading chart...
Decelerating Revenue Growth Masks Underlying Margin Resilience
Investment Thesis • Updated 2026Q1
VerdictNeutral: While the balance sheet is healthy with a 4.61 current ratio
Growth:Decelerating
Profitability:Moderate
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Regulatory and Patent Litigation
Key Thesis Takeaways
- Niagen Bioscience faces a critical inflection point as year-over-year revenue growth has sharply decelerated to 3.3% in 2026Q1, signaling potential market saturation for its core longevity products.
- While the company maintains a robust liquidity position with a 4.61 current ratio, investors should remain cautious regarding the decoupling of accounting profits from cash generation, evidenced by a negative 4.0% free cash flow margin.
- Future performance hinges on the firm's ability to navigate ongoing regulatory and patent litigation while managing the volatility of its operating margins, which have swung from a 24.4% peak in 2024Q4 to 5.0% in 2026Q1.
Verdict Logic
the deceleration of revenue growth to 3.3% and the volatility of free cash flow margins warrant further investigation before committing capital.
NAGE Growth Metrics
Niagen Bioscience Inc (NAGE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years21.89%
5 Years16.91%
3 Years21.56%
TTM20.84%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM32.13%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM26.42%
Return on Capital
10 Years-47.47%
5 Years-22.53%
3 Years7.76%
Last Year20.9%
NAGE Recent Earnings
Niagen Bioscience Inc (NAGE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.07+16.7%
$0.06
Rev
$31M+1.4%
$31M
Q2 2026
Mar 4, 2026Metric
Actual
Est
EPS
$0.03+50.0%
$0.02
Rev
$34M+6.7%
$32M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.05+233.3%
$0.01
Rev
$34M+9.3%
$31M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.04+100.0%
$0.02
Rev
$31M+1.2%
$31M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.07vs $0.06+16.7% | $31Mvs $31M+1.4% |
| Q2 2026 | Mar 4, 2026 | $0.03vs $0.02+50.0% | $34Mvs $32M+6.7% |
| Q4 2025 | Nov 4, 2025 | $0.05vs $0.01+233.3% | $34Mvs $31M+9.3% |
| Q3 2025 | Aug 6, 2025 | $0.04vs $0.02+100.0% | $31Mvs $31M+1.2% |
Based on last 12 quarters of dataView full earnings history →
Latest NAGE News
Recent stock market news and headlines for Niagen Bioscience Inc (NAGE)
Peers Comparison
Key metrics vs top competitors for Niagen Bioscience Inc (NAGE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.45 | $274.77M | 17.25 | 29.95% | 13.43% | 28.35% | — | |
| $4.16 | $71.91M | -3.10 | — | -1070.26% | — | — | |
| $81.57 | $9.68B | 31.86 | 37.55% | 23.13% | 126.27% | — | |
| $177.49 | $17.81B | 38.01 | 21.45% | 21.55% | 21.64% | — | |
| $17.43 | $1.96B | -4.57 | 16.92% | -597.04% | -57.27% | — | |
| $37.92 | $3.9B | -46.81 | 120.01% | -49.17% | -5.89% | — |
Compare NAGE vs Peers
Niagen Bioscience Inc (NAGE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when NAGE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NAGE Frequently Asked Questions
Niagen Bioscience Inc (NAGE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Niagen Bioscience Inc's revenue?
Niagen Bioscience Inc (NAGE) reported $130.4M in revenue for fiscal year 2025.
How fast is Niagen Bioscience Inc growing?
Niagen Bioscience Inc (NAGE) grew revenue by 29.9% over the past year. This is strong growth.
Is NAGE profitable?
Yes, Niagen Bioscience Inc (NAGE) is profitable, generating $18.6M in net income for fiscal year 2025 (13.4% net margin).
Dividend & Returns
What is NAGE's return on equity?
Niagen Bioscience Inc (NAGE) has a return on equity (ROE) of 28.3%. This is excellent, indicating efficient use of shareholder capital.
What is Niagen Bioscience Inc's free cash flow?
Niagen Bioscience Inc (NAGE) generated $4.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.